Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
62
ACAD Quote, Financials, Valuation and Earnings
Last price:
$22.20
Seasonality move
:
5.51%
Day range:
$21.72 - $22.49
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
9.65x
P/S ratio:
3.49x
P/B ratio:
3.07x
Volume:
1.7M
Avg. volume:
2M
1-year change:
33.57%
Market cap:
$3.8B
Revenue:
$1.1B
EPS (TTM):
$2.29
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$305.2M | $0.12 | 15.35% | -21.66% | $31.85 |
|
AXSM
Axsome Therapeutics, Inc.
|
$225.4M | -$0.55 | 50.24% | -36.43% | $223.66 |
|
INSM
Insmed, Inc.
|
$385.6M | -$0.81 | 259.02% | -30.12% | $214.32 |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$348.5M | -$1.41 | 63.79% | -25% | $668.57 |
|
MRK
Merck & Co., Inc.
|
$16.4B | $1.93 | 1.7% | 36.27% | $128.59 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.18 | 95.36% | -52.54% | $7.87 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$22.20 | $31.85 | $3.8B | 9.65x | $0.00 | 0% | 3.49x |
|
AXSM
Axsome Therapeutics, Inc.
|
$168.51 | $223.66 | $8.5B | -- | $0.00 | 0% | 12.88x |
|
INSM
Insmed, Inc.
|
$162.43 | $214.32 | $34.5B | -- | $0.00 | 0% | 53.27x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$546.89 | $668.57 | $13B | -- | $0.00 | 0% | 13.20x |
|
MRK
Merck & Co., Inc.
|
$120.87 | $128.59 | $299.2B | 16.61x | $0.85 | 2.74% | 4.67x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.32 | $7.87 | $21.7M | -- | $0.00 | 0% | 5.44x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.895 | 1.15% | 3.40x |
|
AXSM
Axsome Therapeutics, Inc.
|
71.18% | -0.449 | 2.35% | 1.44x |
|
INSM
Insmed, Inc.
|
50.57% | 1.883 | 2.03% | 3.35x |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
36.58% | -1.826 | 2.61% | 3.62x |
|
MRK
Merck & Co., Inc.
|
49% | -0.565 | 20.22% | 0.94x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 1.671 | -- | 7.49x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AXSM
Axsome Therapeutics, Inc.
|
$181.4M | -$36M | -64.52% | -265.23% | -18.38% | -$18.7M |
|
INSM
Insmed, Inc.
|
$217.7M | -$249.7M | -77.98% | -192.35% | -94.64% | -$294.2M |
|
MDGL
Madrigal Pharmaceuticals, Inc.
|
$296.2M | -$59.6M | -32.42% | -42.53% | -18.57% | -$133.1M |
|
MRK
Merck & Co., Inc.
|
$11.5B | $6.2B | 20.34% | 36.76% | 37.74% | $1.8B |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$1.9M | -77.25% | -77.25% | -170.75% | -$1.9M |
ACADIA Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ACAD or AXSM?
Axsome Therapeutics, Inc. has a net margin of 96.33% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -14.57%. ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78% beat Axsome Therapeutics, Inc.'s return on equity of -265.23%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B AXSMAxsome Therapeutics, Inc.92.55% -$0.56 $306.4M -
What do Analysts Say About ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.85, signalling upside risk potential of 43.47%. On the other hand Axsome Therapeutics, Inc. has an analysts' consensus of $223.66 which suggests that it could grow by 32.73%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Axsome Therapeutics, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Axsome Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.12 4 1 AXSMAxsome Therapeutics, Inc.17 1 0 -
Is ACAD or AXSM More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.833, which suggesting that the stock is 16.67% less volatile than S&P 500. In comparison Axsome Therapeutics, Inc. has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.123%.
-
Which is a Better Dividend Stock ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Axsome Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or AXSM?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $284M, which are larger than Axsome Therapeutics, Inc. quarterly revenues of $196M. ACADIA Pharmaceuticals, Inc.'s net income of $273.6M is higher than Axsome Therapeutics, Inc.'s net income of -$28.6M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 9.65x while Axsome Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.49x versus 12.88x for Axsome Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M AXSMAxsome Therapeutics, Inc.12.88x -- $196M -$28.6M
-
Which has Higher Returns ACAD or INSM?
Insmed, Inc. has a net margin of 96.33% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -124.5%. ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78% beat Insmed, Inc.'s return on equity of -192.35%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B INSMInsmed, Inc.82.51% -$1.54 $1.5B -
What do Analysts Say About ACAD or INSM?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.85, signalling upside risk potential of 43.47%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Insmed, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Insmed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.12 4 1 INSMInsmed, Inc.17 0 0 -
Is ACAD or INSM More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.833, which suggesting that the stock is 16.67% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.
-
Which is a Better Dividend Stock ACAD or INSM?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or INSM?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $284M, which are larger than Insmed, Inc. quarterly revenues of $263.8M. ACADIA Pharmaceuticals, Inc.'s net income of $273.6M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 9.65x while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.49x versus 53.27x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M INSMInsmed, Inc.53.27x -- $263.8M -$328.5M
-
Which has Higher Returns ACAD or MDGL?
Madrigal Pharmaceuticals, Inc. has a net margin of 96.33% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -18.24%. ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B MDGLMadrigal Pharmaceuticals, Inc.92.26% -$2.57 $950.3M -
What do Analysts Say About ACAD or MDGL?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.85, signalling upside risk potential of 43.47%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $668.57 which suggests that it could grow by 22.25%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.12 4 1 MDGLMadrigal Pharmaceuticals, Inc.11 2 0 -
Is ACAD or MDGL More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.833, which suggesting that the stock is 16.67% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -0.995, suggesting its less volatile than the S&P 500 by 199.535%.
-
Which is a Better Dividend Stock ACAD or MDGL?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or MDGL?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $284M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $321.1M. ACADIA Pharmaceuticals, Inc.'s net income of $273.6M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 9.65x while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.49x versus 13.20x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M MDGLMadrigal Pharmaceuticals, Inc.13.20x -- $321.1M -$58.6M
-
Which has Higher Returns ACAD or MRK?
Merck & Co., Inc. has a net margin of 96.33% compared to ACADIA Pharmaceuticals, Inc.'s net margin of 18.15%. ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78% beat Merck & Co., Inc.'s return on equity of 36.76%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B MRKMerck & Co., Inc.70.49% $1.19 $103.2B -
What do Analysts Say About ACAD or MRK?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.85, signalling upside risk potential of 43.47%. On the other hand Merck & Co., Inc. has an analysts' consensus of $128.59 which suggests that it could grow by 6.11%. Given that ACADIA Pharmaceuticals, Inc. has higher upside potential than Merck & Co., Inc., analysts believe ACADIA Pharmaceuticals, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.12 4 1 MRKMerck & Co., Inc.15 10 0 -
Is ACAD or MRK More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.833, which suggesting that the stock is 16.67% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.266, suggesting its less volatile than the S&P 500 by 73.446%.
-
Which is a Better Dividend Stock ACAD or MRK?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.74% to investors and pays a quarterly dividend of $0.85 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ACAD or MRK?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $284M, which are smaller than Merck & Co., Inc. quarterly revenues of $16.3B. ACADIA Pharmaceuticals, Inc.'s net income of $273.6M is lower than Merck & Co., Inc.'s net income of $3B. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 9.65x while Merck & Co., Inc.'s PE ratio is 16.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.49x versus 4.67x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M MRKMerck & Co., Inc.4.67x 16.61x $16.3B $3B
-
Which has Higher Returns ACAD or MRKR?
Marker Therapeutics, Inc. has a net margin of 96.33% compared to ACADIA Pharmaceuticals, Inc.'s net margin of -154.36%. ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78% beat Marker Therapeutics, Inc.'s return on equity of -77.25%.
Company Gross Margin Earnings Per Share Invested Capital ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B MRKRMarker Therapeutics, Inc.-- -$0.10 $16.8M -
What do Analysts Say About ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. has a consensus price target of $31.85, signalling upside risk potential of 43.47%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 495.96%. Given that Marker Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ACADACADIA Pharmaceuticals, Inc.12 4 1 MRKRMarker Therapeutics, Inc.3 0 0 -
Is ACAD or MRKR More Risky?
ACADIA Pharmaceuticals, Inc. has a beta of 0.833, which suggesting that the stock is 16.67% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.471, suggesting its more volatile than the S&P 500 by 47.131%.
-
Which is a Better Dividend Stock ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ACAD or MRKR?
ACADIA Pharmaceuticals, Inc. quarterly revenues are $284M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.1M. ACADIA Pharmaceuticals, Inc.'s net income of $273.6M is higher than Marker Therapeutics, Inc.'s net income of -$1.7M. Notably, ACADIA Pharmaceuticals, Inc.'s price-to-earnings ratio is 9.65x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals, Inc. is 3.49x versus 5.44x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ACADACADIA Pharmaceuticals, Inc.3.49x 9.65x $284M $273.6M MRKRMarker Therapeutics, Inc.5.44x -- $1.1M -$1.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 5
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 4
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 4
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
